Literature DB >> 19743998

Underlying mechanism of portal hypertensive gastropathy in cirrhosis: a hemodynamic and morphological approach.

Lílian Amorim Curvêlo1, Walnei Brabosa, Rachel Rhor, Valéria Lanzoni, Edison Roberto Parise, Angelo Paulo Ferrari, Mario Kondo.   

Abstract

BACKGROUND AND AIM: Portal hypertensive gastropathy (PHG) is an important cause of bleeding in patients with cirrhosis associated with portal hypertension. Histologically, the condition is characterized by dilation of the mucosal and submucosal vessels of the stomach; however, its mechanisms remain unclear. The aim of the present cross-sectional study was to evaluate the role of portal and systemic hemodynamic features, humoral factors and hepatocellular function in the development and severity of PHG in patients with cirrhosis.
METHODS: Forty-six patients with cirrhosis of different etiologies underwent endoscopy. Portal hypertension was evaluated by hepatic venous pressure gradient (HVPG). The gastric mucosa was analyzed using two diagnostic methods: endoscopy according to the McCormack criteria and histological by histomorphometric analysis.
RESULTS: The prevalence of PHG according to the endoscopic and histomorphometric methods was 93.4% and 76.1%, respectively. There were no statistically significant differences in HVPG measurements between the patients with mild (16.0 +/- 5.9 mmHg) and severe PHG (16.9 +/- 6.5 mmHg; P = 0.80) or between patients who did not have (15.2 +/- 8.0 mmHg) and those who had PHG (16.3 +/- 5.7 mmHg). No correlation was found between the presence or severity of PHG and systemic vascular resistance index (P = 0.53 and 0.34, respectively), Child-Pugh classification (P = 0.73 and 0.78, respectively) or glucagon levels (P = 0.59 and 0.62, respectively).
CONCLUSIONS: The present data show no correlation between the presence or the severity of PHG and portal pressure, Child-Pugh classification or systemic hemodynamics, suggesting that other factors may be involved in the physiopathology of PHG, such as local gastric mucosal factors or other underlying factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19743998     DOI: 10.1111/j.1440-1746.2009.05871.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

2.  The Portal Hypertensive Gastropathy: A Case and Review of Literature.

Authors:  Francesco Massoni; Lidia Ricci; Marcello Pelosi; Serafino Ricci
Journal:  J Clin Diagn Res       Date:  2016-06-01

3.  Portal hypertensive gastropathy is associated with iron deficiency anemia.

Authors:  Benedikt Simbrunner; Andrea Beer; Katharina Wöran; Fabian Schmitz; Christian Primas; Marlene Wewalka; Matthias Pinter; Werner Dolak; Bernhard Scheiner; Andreas Puespoek; Michael Trauner; Georg Oberhuber; Mattias Mandorfer; Thomas Reiberger
Journal:  Wien Klin Wochenschr       Date:  2020-01-07       Impact factor: 1.704

4.  Effect of Helicobacter pylori and its virulence factors on portal hypertensive gastropathy and interleukin (IL)-8, IL-10, and tumor necrosis factor-alpha levels.

Authors:  Zaigham Abbas; Javed Yakoob; Muhammad W Usman; Tanzila Shakir; Saeed Hamid; Wasim Jafri
Journal:  Saudi J Gastroenterol       Date:  2014 Mar-Apr       Impact factor: 2.485

5.  Portal hypertensive gastropathy as a prognostic index in patients with liver cirrhosis.

Authors:  Chang Seok Bang; Hyo Sun Kim; Ki Tae Suk; Sung Eun Kim; Ji Won Park; Seung Ha Park; Hyoung Su Kim; Myoung Kuk Jang; Sang Hoon Park; Myung Seok Lee; Choong Kee Park; Dong Joon Kim
Journal:  BMC Gastroenterol       Date:  2016-08-12       Impact factor: 3.067

6.  Portal Hypertensive Polyps as Gastroscopic Finding in Liver Cirrhosis.

Authors:  Firdevs Topal; Sabiye Akbulut; Cengiz Karahanlı; Süleyman Günay; Elif Sarıtaş Yüksel; Fatih Esad Topal
Journal:  Gastroenterol Res Pract       Date:  2020-02-26       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.